Novartis wins FDA staff Ok for Neupogen generic

Move could make generic biologic therapies more accessible in the U.S.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.